This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cancer and the immune system

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cancer and the immune system

  • basic role of our immune system is to protect human beings against foreign pathogens and also infections
    • immune responses consist of two types:
      • humoral immunity and cellular immunity, which are mediated by B and T lymphocytes as well as their products
        • humoral immunity can neutralize and eradicate outside microbes and toxins via antibodies produced by B cells
        • cellular immunity responds more quickly to eradicate intracellular microbes through recognition of antigens, activation of antigen presenting cells (APCs), activation and proliferation of T cells.

Both innate and adaptive immune systems play important roles in anticancer immune response

  • innate immune cells can release signals which are essential to stimulate responses from both T cells and B cells

  • adaptive immune system is mainly consists of B cells, CD8+ cytotoxic T cells as well as CD4+ helper T cells

    • APCs perform a bridge between the innate and the adaptive immune system by recognizing foreign antigens and presenting to the naive T cells
      • after activation of toll-like receptors on dendritic cells (DCs), factors on the DC surface essential to antigen presentation are increased - cytokines that facilitate the adaptive immune response are promoted

    • Antigen presentation stimulates T cells to become either "cytotoxic" CD8+ cells or "helper" CD4+ cells (1)


  • CD8+ cytotoxic T lymphocytes (CTLs) are fundamental in the immune response fighting cancer
    • tumour-infiltrating lymphocytes (TILs) contain an abundant level of CTLs capable of invading malignant cells
    • tumour antigen recognition
      • necessary prerequisite for the effective antitumour immune response
      • presentation mediated by direct presentation which cancer cells drain in the lymph node or via cross-presentation by pAPC
        • professional antigen presenting cells (pAPCs) are immune cells that specialize in presenting an antigen to a T-cell
        • main types of pAPCs are dendritic cells (DC), macrophages, and B cells
        • pAPC takes up an antigen, processes it, and returns part of it to its surface, along with a class II major histocompatibility complex (MHC)
        • the T-cell is activated when it interacts with the formed complex

    • cross priming of naive CD8+ T cells by pAPC invokes a program leading to tumour specific CTLs proliferating and trafficking to the tumour sites where they will finally attack cancer cells
      • CTLs can attack tumour cells via perforin, granzymes and also ligands of the tumour necrosis factor (TNF) superfamily
      • anti-tumour effect can also be achieved by secreting Interferon gamma and TNF-alpha from activated CD8+ T cells

  • naive CD4+ T cells could be activated and differentiated into distinct T cell subsets
    • Th1, Th2, Tregs, Th9, Th17, Th22 and also follicular helper T cells once they encounter antigens and also adequate co-stimulation signals
    • Th1 subset of CD4+ T cells play crucial antitumour roles by coordinating cell mediated immunity against cancer
      • enhance CD8+ T cells expansion, priming and infiltration into the tumour site
      • activate inflammatory cells, such as macrophages, NK cells, granulocytes and eosinophils in around the tumour
      • can kill MHC-II+ tumour cells by releasing perforin and granzyme, and also by TNF-related apoptosis inducing ligand receptor and Fas/Fas ligand pathways

  • NK cells can destroy cancer cells directly via:
    • secretion of TNF-alpha, perforin, cytoplasmic granules and granzymes, expression of death receptor-mediated apoptosis, and expression of CD16 which leads to antibody dependent cellular cytotoxicity (ADCC)
    • NK cells have been able to have antitumour activity as well indirectly by chemokines, cytokines and growth factors production

  • macrophages can be characterized as pro-inflammatory M1 or anti-inflammatory M2 macrophages:
    • M1 macrophages secrete pro-inflammatory cytokines boost antitumour immunity
    • M2 macrophages produce anti-inflammatory cytokines which would promote tumourigenesis

Reference:

  • By user:Sjef - self made, http://commons.wikimedia.org/wiki/Image:Antigen_presentation.jpg, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=4470656
  • Brooks M, Olsson-Brown A. Summary on Immunotherapy for Palliative Care Teams (Accessed 1/12/19)
  • Haanan J et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology 2017; 28 (Supplement 4)
  • Zhang H, Jibei C. Current status and future directions of cancer immunotherapy. Journal of Cancer 2018; 9(10): 1773-1781.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.